NASDAQ:PPBT Purple Biotech (PPBT) Stock Price, News & Analysis $2.32 -0.03 (-1.28%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.34 +0.02 (+0.86%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Purple Biotech Stock (NASDAQ:PPBT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Purple Biotech alerts:Sign Up Key Stats Today's Range$2.25▼$2.4550-Day Range$2.32▼$3.0552-Week Range$2.00▼$20.60Volume77,858 shsAverage Volume268,788 shsMarket Capitalization$3.09 millionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingBuy Company OverviewPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Read More… Purple Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScorePPBT MarketRank™: Purple Biotech scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPurple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePurple Biotech has received no research coverage in the past 90 days.Read more about Purple Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Purple Biotech are expected to decrease in the coming year, from ($0.83) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Purple Biotech is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Purple Biotech is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPurple Biotech has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Purple Biotech's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.87% of the float of Purple Biotech has been sold short.Short Interest Ratio / Days to CoverPurple Biotech has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Purple Biotech has recently decreased by 13.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPurple Biotech does not currently pay a dividend.Dividend GrowthPurple Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.87% of the float of Purple Biotech has been sold short.Short Interest Ratio / Days to CoverPurple Biotech has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Purple Biotech has recently decreased by 13.53%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.92 News SentimentPurple Biotech has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Purple Biotech this week, compared to 1 article on an average week.Search Interest1 people have searched for PPBT on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Purple Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.98% of the stock of Purple Biotech is held by insiders.Percentage Held by InstitutionsOnly 9.64% of the stock of Purple Biotech is held by institutions.Read more about Purple Biotech's insider trading history. Receive PPBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address PPBT Stock News HeadlinesPurple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic CancerApril 30 at 7:41 AM | tipranks.comPurple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck CancersApril 28, 2025 | globenewswire.comBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 3, 2025 | Crypto 101 Media (Ad)Purple Biotech announces publication of study on potential of NT219April 17, 2025 | markets.businessinsider.comPurple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research MeetingMarch 28, 2025 | finance.yahoo.comPurple Biotech Unveils Updated Oncology Pipeline ProgressMarch 18, 2025 | tipranks.comPurple Biotech Reports Positive Clinical Trial Results for CM24 and NT219, Advancing to Phase 2 StudiesMarch 12, 2025 | nasdaq.comPurple Biotech reports Q4 EPS (26c) vs. ($3.80) last yearMarch 10, 2025 | markets.businessinsider.comSee More Headlines PPBT Stock Analysis - Frequently Asked Questions How have PPBT shares performed this year? Purple Biotech's stock was trading at $4.69 at the beginning of the year. Since then, PPBT stock has decreased by 50.5% and is now trading at $2.32. View the best growth stocks for 2025 here. How were Purple Biotech's earnings last quarter? Purple Biotech Ltd (NASDAQ:PPBT) released its quarterly earnings results on Monday, March, 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. When did Purple Biotech's stock split? Shares of Purple Biotech reverse split on the morning of Tuesday, September 17th 2024. The 1-20 reverse split was announced on Friday, September 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Purple Biotech's major shareholders? Top institutional shareholders of Purple Biotech include Kingswood Wealth Advisors LLC (1.26%). How do I buy shares of Purple Biotech? Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Purple Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings3/10/2025Today5/03/2025Next Earnings (Estimated)5/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PPBT Previous SymbolNASDAQ:KTOV CIK1614744 Webwww.kitovpharma.com Phone(723) 933-3121Fax972-153-39333121Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$33.00 Low Stock Price Target$33.00 Potential Upside/Downside+1,322.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.86% Return on Assets-44.67% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$27.18 per share Price / Book0.09Miscellaneous Outstanding Shares1,331,000Free Float1,291,000Market Cap$3.09 million OptionableOptionable Beta0.62 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:PPBT) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.